Disease relevance of SLC25A16

• We have investigated the role of myosin II in glioma motility and invasiveness by examining the effects of two inhibitors of myosin light chain kinase, ML7 and KT5926 [1].
• RESULTS: All aneurysms were cured with GDC embolization [2].
• We present a case of delayed thromboembolic events that occurred 9 weeks after endovascular treatment of an anterior communicating artery aneurysm with GDC [3].
• METHODS: Autopsies were performed on six patients with acute subarachnoid hemorrhage who had died between 5 and 272 days after GDC treatment [4].
• In the GDC-treated aneurysms, evidence of early thrombus organization was observed within 2-3 months, and completed yet imperfect fibrocellular reaction together with residual thrombus at 2-3 years [5].

High impact information on SLC25A16

• MT movement was not inhibited when MT assembly was suppressed with nocodazole or Taxol; MT movement was suppressed by inhibition of myosin light chain kinase with ML7 or by a peptide inhibitor [6].
• 0. The deduced amino acid sequence of the C-terminal half of the molecule revealed 78% homology to Grave disease carrier protein and 67% homology to human ADP/ATP translocase; this sequence homology identified the protein as a new member of the mitochondrial transporter superfamily [7].
• Cells treated with BDM/ML7 or those that express the MRLC2(AA) mutant revealed a significant reduction in the brefeldin A (BFA)-induced fusion of Golgi enzymes with the endoplasmic reticulum (ER) [8].
• Neither the reassembly of the Golgi complex after BFA removal nor VSV-G transport from ER to the Golgi was altered in cells treated with BDM/ML7 or expressing MRLC2(AA) [8].
• Inhibitors of ROK (dominant-negative ROK and Y-27632) and of the downstream target of ROK, myosin-II (ML7, BDM, and dominant-negative myosin-II), were used to test this idea [9].

Chemical compound and disease context of SLC25A16

• We report 28 patients with nonsurgical intracranial aneurysms referred by neurosurgeons for endovascular treatment using platinum detachable coils (GDC, Target Therapeutics, Fremont, Calif., USA) [10].
• Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate [11].
• MLW1, an antigen preparation from Mycobacterium leprae previously shown to have a high content of M. leprae antigen No. 7 (ML7), was found to contain the typical cell wall constituents arabinose, galactose and mannose [12].

Biological context of SLC25A16

• The gene represented by the hML-7 cDNA has been assigned to human chromosome 10 [13].
• Treatment with ML7, in contrast, resulted in a marginal inhibition of MLC phosphorylation and gel contraction [14].
• CONCLUSION: We postulate that within days after GDC treatment, blood clotting and thrombus formation prevent rebleeding and that solid scar formation covered by a layer of long slender cells, resembling endothelium, seals the aneurysm over time [4].
• Thus the key reaction of photorespiration catalyzed by GDC, together with the key reaction of CO(2) fixation catalyzed by ribulose-1,5-bisphosphate carboxylase, both contribute to carbon isotope fractionation in photosynthesis [15].

Anatomical context of SLC25A16

• The cDNA from hML-7 was sequenced and compared with the sequence of cross-hybridizing cDNA clones isolated from human Graves' thyroid and rat FRTL-5 thyroid cell lambda gt11 expression libraries [13].
• Neutral GDCEP showed more rapid degradation than negatively charged GDCP in the blood plasma [16].
• Transcatheter embolization is a reasonable and less invasive mode in the treatment of systemic artery to pulmonary artery fistula, and GDC offers more precise coil placement over other conventional coils [17].
• Attempts to remove the ML7 antigen indicate that this component plays a dominant role in inducing in vitro lymphocyte stimulation [12].
• Successful staged treatment for ruptured blister-like dissecting aneurysm of the intracranial internal carotid artery: acute GDC embolization for the blister-like aneurysm followed by proximal occlusion with extracranial-intracranial bypass in the chronic stage [18].

Associations of SLC25A16 with chemical compounds

• A negatively charged polydisulfide Gd(III) complex, (Gd-DTPA)-cystine copolymers (GDCP), and a neutral agent, (Gd-DTPA)-cystine diethyl ester copolymers (GDCEP), with different molecular weights were prepared and characterized [16].
• One of the cell-types contains dopamine (GDC), the other serotonin (GSC) and the other neither amine (GC) [19].
• The contribution of Rho-kinase and/or MLC-kinase was also evaluated using respective kinase inhibitors (Y27632, hydroxyfasudil and ML7) [14].
• Transcatheter Guglielmi Detachable Coil (GDC; Target Ther, Fremont, Calif.) embolization was performed [17].
• GDC (gemcitabine 750 mg/m(2), on days 1 and 8; docetaxel 50 mg/m(2), on day 1; carboplatin 200 mg/m(2) on day 1) was administered every 21 days to 9 patients [20].

Analytical, diagnostic and therapeutic context of SLC25A16

• Multichannel EEG as sequence of momentary brain field maps constitutes a trajectory through K-dimensional state space (K = number of channels); the complexity of this trajectory is assessed by the nonlinear measure of global correlation dimension (Global Dimensional Complexity, GDC) with the number of electrodes as embedding dimension [21].
• Retreatment was performed in 16 of 120 aneurysms (13.3%) treated with GDC 10 coils and in nine of 115 aneurysms (7.8%) treated with Cordis TruFill coils [22].
• This is the first report of chemotherapy with GDC against patients with SCCP [11].
• Concordance was high between the GDC ELISA assay and GC/MS and with results reported earlier for other commercial assays [23].
• RESULTS: Ninety endovascular procedures were performed on 71 aneurysms: GDC coiling in 78 (including 45 with the remodeling technique), permanent balloon occlusion in 9, and 3 had both GDC coiling and permanent balloon occlusion [24].

References